, Volume 73, Issue 2, pp 187–193 | Cite as

Fluocinolone Acetonide Intravitreal Implant (Iluvien®)

In Diabetic Macular Oedema
  • Mark SanfordEmail author
Adis Drug Profile


Fluocinolone acetonide intravitreal implant (Iluvien®) is an injectable, non-erodible, corticosteroid implant that is approved in several European countries for the treatment of chronic diabetic macular oedema (DMO). In analyses of two multinational trials in patients with DMO previously treated with macular laser photocoagulation, fluocinolone acetonide intravitreal implant 0.2 μg/day was significantly more efficacious than sham injection in improving visual acuity. At 24 months post injection, 29 % of fluocinolone acetonide intravitreal implant 0.2 μg/day recipients had an improvement in the best-corrected visual acuity (BCVA) letter score of ≥15 compared with 16 % in the sham injection group (p = 0.002) [primary endpoint]. Treatment benefit was most evident in the subgroup of patients whose duration of DMO was ≥3 years. In this subgroup at 36 months, 34 % of fluocinolone acetonide intravitreal implant 0.2 μg/day recipients had an increase in the BCVA score of ≥15, compared with 13 % of sham injection recipients (p < 0.001). Fluocinolone acetonide intravitreal implant recipients also had generally greater benefits than sham injection recipients on secondary endpoints. In patients who were phakic in the study eye at baseline, cataracts occurred in 82 % of fluocinolone acetonide intravitreal implant 0.2 μg/day recipients and 51 % of sham injection recipients. Overall, 37 % and 12 % of patients in the fluocinolone acetonide intravitreal implant and sham injection groups developed raised intraocular pressure (IOP), which was generally controlled with IOP-lowering drugs.


Diabetic Retinopathy Diabetic Macular Oedema Foveal Thickness Vascular Endothelial Growth Factor Inhibitor Posterior Capsule Opacification 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer was offered an opportunity to comment on this article. Changes resulting from any comments received were made by the author on the basis of scientific and editorial merit.


  1. 1.
    Blumenkranz MS. Optimal current and future treatments for diabetic macular oedema. Eye. 2010;24(3):428–34.PubMedCrossRefGoogle Scholar
  2. 2.
    Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–64.PubMedCrossRefGoogle Scholar
  3. 3.
    Bhagat N, Grigorian RA, Tutela A, et al. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1–32.PubMedCrossRefGoogle Scholar
  4. 4.
    Eljarrat-Binstock E, Pe’er J, Domb AJ. New techniques for drug delivery to the posterior eye segment. Pharm Res. 2010;27(4):530–43.PubMedCrossRefGoogle Scholar
  5. 5.
    Bausch & Lomb Inc. Retisert (fluocinolone acetonide intravitreal implant) 0.59 mg for intravitreal use: US prescribing information; 2011. Accessed 21 November 2012.
  6. 6.
    Pearson PA, Cornstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled trial. Ophthalmology. 2011;118(8):1580–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Medicine and Healthcare products Regulatory Agency. Iluvien 190 micrograms intravitreal implant in applicator: summary of product characteristics; 2012. Accessed 19 November 2012.
  8. 8.
    Grover D, Li TJ, Chong CCW. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2008(1):CD005656.Google Scholar
  9. 9.
    Jobling AI, Augusteyn RC. What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin Exp Optom. 2002;85(2):61–75.PubMedCrossRefGoogle Scholar
  10. 10.
    Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye. 2006;20:407–16.PubMedCrossRefGoogle Scholar
  11. 11.
    Campochiaro PA, Nguyen QD, Hafiz G, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Opthalmology. 2012;. doi: 10.1016/j.optha.2012.09.014.Google Scholar
  12. 12.
    Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626–35.e2.Google Scholar
  13. 13.
    Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–32.PubMedCrossRefGoogle Scholar
  14. 14.
    Alimera Sciences Inc. Fluocinolone acetonide in diabetic macular edema (FAME) extension study. 2012. Accessed 19 November 2012.

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.AdisNorth ShoreNew Zealand

Personalised recommendations